Needham & Company LLC Reaffirms Hold Rating for Envista (NYSE:NVST)

Envista (NYSE:NVST)‘s stock had its “hold” rating reiterated by investment analysts at Needham & Company LLC in a report released on Thursday,Benzinga reports.

A number of other analysts have also recently commented on the company. Jefferies Financial Group boosted their price objective on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd. Leerink Partners raised Envista from an “underperform” rating to a “market perform” rating and upped their price objective for the stock from $16.00 to $23.00 in a research report on Thursday, October 31st. Mizuho started coverage on Envista in a research note on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price target for the company. Stifel Nicolaus boosted their target price on Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Finally, Piper Sandler increased their price target on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Envista presently has a consensus rating of “Hold” and a consensus target price of $20.21.

Envista Trading Up 2.2 %

NVST stock opened at $20.58 on Thursday. The company has a market capitalization of $3.54 billion, a price-to-earnings ratio of -2.65, a PEG ratio of 1.82 and a beta of 1.34. Envista has a 1-year low of $15.15 and a 1-year high of $24.79. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. The business has a 50 day simple moving average of $19.97 and a two-hundred day simple moving average of $19.10.

Envista (NYSE:NVST) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. Research analysts anticipate that Envista will post 0.72 EPS for the current fiscal year.

Institutional Trading of Envista

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE increased its stake in shares of Envista by 340.9% in the fourth quarter. US Bancorp DE now owns 21,919 shares of the company’s stock worth $423,000 after purchasing an additional 16,948 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in Envista in the fourth quarter valued at approximately $358,000. Amalgamated Bank grew its position in shares of Envista by 0.7% in the 4th quarter. Amalgamated Bank now owns 80,380 shares of the company’s stock worth $1,551,000 after buying an additional 523 shares during the last quarter. Hudson Edge Investment Partners Inc. raised its stake in Envista by 4.8% in the fourth quarter. Hudson Edge Investment Partners Inc. now owns 24,931 shares of the company’s stock worth $481,000 after buying an additional 1,150 shares in the last quarter. Finally, Paradice Investment Management LLC grew its stake in Envista by 3.8% in the fourth quarter. Paradice Investment Management LLC now owns 1,652,332 shares of the company’s stock worth $31,873,000 after purchasing an additional 61,139 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.